OLIG2 Immunolabeling of Mesenchymal Chondrosarcoma: Report of 14 Cases.

Mesenchymal chondrosarcoma (MC) is a rare aggressive mesenchymal sarcoma. Specific markers for the differential diagnosis of MCs remain to be developed. OLIG2 expression has been reported only in neuroepithelial tumors. Recently, OLIG2 expression was found to be involved in the development of NCOA2 fusion-positive alveolar rhabdomyosarcomas. Therefore, we investigated whether OLIG2 expression could be used as a diagnostic marker for MC. We report the clinical pathological and immunohistochemical features of 14 MCs. All tumors showed typical pathological features including biphasic patterns with sheets of primitive round mesenchymal cells and interspersed islands of cartilage. These tumors expressed BCL2, SOX9, and CD99. OLIG2 was robustly expressed in 12/14 of MCs. NCOA2 rearrangement was found in 12 cases. OLIG2 expression was not found in the NCOA2 rearrangement-negative MCs. Notably, OLIG2 expression was not detected in 52 neoplasms (8 Ewing sarcomas, 23 hemangiopericytomas, and 21 chondrosarcomas) that are frequently misdiagnosed as MC. Our findings provide convincing evidence that OLIG2 can serve as a reliable marker in the differential diagnosis of MC and may be a unique neurodevelopmental gene expression signature for the NCOA2 rearranged MCs.

[1]  Emily J. Girard,et al.  Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. , 2019, Cancer cell.

[2]  A. Folpe,et al.  OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma. , 2019, Human pathology.

[3]  Yin Wang,et al.  Detection of H3K27M mutation in cases of brain stem subependymoma. , 2019, Human pathology.

[4]  F. Ghaffarpasand,et al.  Whorling-Sclerosing Variant Meningioma of the Spine: Surgical Management and Outcome of an Extremely Rare Case , 2018, Spine.

[5]  M. Miyake,et al.  Minute mesenchymal chondrosarcoma within osteochondroma: an unexpected diagnosis confirmed by HEY1-NCOA2 fusion. , 2018, Human pathology.

[6]  A. Lazar,et al.  Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology , 2018, Current Oncology Reports.

[7]  S. Kakar,et al.  Pancreatic involvement by mesenchymal chondrosarcoma harboring the HEY1-NCOA2 gene fusion. , 2016, Human pathology.

[8]  A. Bahrami,et al.  Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review , 2015, Sarcoma.

[9]  F. Kawakami,et al.  Central neurocytoma with ependymoma-like glial component , 2015, Brain Tumor Pathology.

[10]  C. Decaestecker,et al.  Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms , 2014, Tumor Biology.

[11]  B. Bjerkehagen,et al.  Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma , 2014, Oncology reports.

[12]  Y. Mao,et al.  Olig2‐positive cells in glioneuronal tumors show both glial and neuronal characters: The implication of a common progenitor cell? , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.

[13]  M. Dexter,et al.  Diagnostic pitfall in the diagnosis of mesenchymal chondrosarcoma arising in the central nervous system , 2012, Neuropathology : official journal of the Japanese Society of Neuropathology.

[14]  John H. Postlethwait,et al.  Development and Stem Cells Research Article , 2022 .

[15]  A. Olshen,et al.  Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomas , 2007, The Journal of pathology.

[16]  T. Triche,et al.  Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. , 2006, Cancer research.

[17]  B. Czerniak,et al.  Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. , 2003, Human pathology.

[18]  M. Wegner,et al.  Expression of Transcription Factors during Oligodendroglial Development , 2022 .

[19]  K. Unni,et al.  Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases , 1986, Cancer.

[20]  L. Lichtenstein,et al.  Unusual benign and malignant chondroid tumors of bone. A survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas , 1959, Cancer.